5-Bromo-3-hydroxy-2-nitropyridine was used to design potent and selective inhibitors to overcome clinical anaplastic Lymphoma kinase mutations resistant to Crizotinib (C785000), a potential antitumor agent.
參考文獻
Huang, Q., et al.: J. Med. Chem., 57, 1170 (2014); Zou, H.Y. et al.: Cancer Res., 67, 4408 (2007); Cui, J.J. et al.: J. Med. Chem., No pp given (2011); Sasaki, T. et al.: Cancer. Res. et al.: 70, 10038 (2010);